DALLAS, Texas, Nov. 7 [Category: Health Care] -- The American Heart Association posted the following news release:

* * *

Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral

*

Research Highlights:

* In the 7-year, phase III, multicenter, international Lp(a) HORIZON trial, the novel medication pelacarsen lowered Lp(a) levels by a mean of 78% in a trial with more than 8,300 adults with cardiovascul . . .

Click here for more information about our products